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poorly to conventional myeloma treatment. Recently it has been
shown that melphalan doses up to 140 mg/m2 without HPC sup-
port can be given safely to myeloma patients. We report our
experience with the use of HDM without HPC support in 3
patients with PPCL. All patients received HDM (140 mg/m2) as a
single 40-minute IV infusion. Filgrastim (6 g/kg/day) was started
24 hours after HDM and continued until absolute neutrophil
count (ANC) was  500/L. There was complete clearance of
plasma cells from the bone marrow and resolution of cytogenetic
abnormalities. IgG level in patient 1 and M-protein level in pa-
tients 2 and 3 decreased by  75% before thalidomide initiation
and was maintained for  6 weeks. One patient (case 1) had
extramedullary disease progression evidenced on day 130 and ex-
pired despite further treatment with VAD, arsenic trioxide, meth-
ylprednisolone, and thalidomide. Patient 2 achieved CR after re-
ceiving allogeneic stem cell transplantation from a matched sibling
donor at day 137 and remains in complete remission. There was no
treatment-related mortality. Treatment of PPCL with HDM with-
out HPC support was well tolerated. It resulted in prompt hema-
tologic recovery and produced dramatic control of an otherwise
rapidly fatal process. Such treatment may be a viable option when
HPC transplantation is not feasible.
Table 1. Patient Characteristics
Age
(y)/
Sex
WBC
(1000/
l)/BM
Involve-
ment
M-protein
Level (g/
dl)/Ig Type
Prior Rx/
Response
Count
Recovery
(D 0)
Thalido-
mide
Started
(D 0)
Best
Documented
Response/
Day (D 0)
TTP/
Survival
(Days)
50/
M
60.5/
100%
Not
available/
IgG
High-dose
cortico-
steroids/
progres-
sive
disease
20 NA PR/120 130/423
45/F 54.6/
100%
3.54/IgG High-dose
cortico-
steroids/
Progres-
sive
disease
20 30 PR/30 NA/557
66/F 17.3/
75%
4.5/IgG VAD/
progres-
sive
disease
36 100 PR/164 NA/219
TTP: time to progression, NA: not applicable, PR: partial re-
sponse.
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BORTEZOMIB DOES NOT ADVERSELY AFFECT STEM CELL MOBILIZA-
TION AND ENGRAFTMENT IN PATIENTS WITH MULTIPLE MYELOMA
UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Uy, G.L., Fisher, N.M., Devine, S.M., Adkins, D.R., Tomasson, M.H.,
Graubert, T.A., DiPersio, J.F., Vij, R. Washington University School of
Medicine, St. Louis, MO.
Bortezomib (Velcade) is a selective inhibitor of the 26S protea-
some approved for the treatment of relapsed or refractory multiple
myeloma (MM). The role of bortezomib in front-line therapy for
MM is undeﬁned and will depend in part on its effects on subse-
quent stem cell mobilization and engraftment. We conducted a
pilot study of bortezomib administered pretransplantation fol-
lowed by high-dose melphalan with autologous hematopoietic
stem cell transplantation (AHSCT). Two cycles of bortezomib 1.3
mg/m2 were administered on days 1, 4, 8, and 11 of a 21-day
treatment cycle. One week after completion of bortezomib, stem
cells were mobilized with G-CSF 10 g/kg/day for 5 days and
harvested by large-volume apheresis (20 L/day) until a minimum of
2.5  106 CD34 cells/kg were collected. Melphalan 100 mg/m2/
day for 2 days was administered, followed by reinfusion of periph-
eral blood stem cells 48 hours later. GM-CSF 250 g/m2/day was
given posttransplantation until neutrophil engraftment occurred.
To date, 32 of a planned 40 patients have been enrolled in this
study, with 23 patients having completed their initial therapy with
bortezomib followed by AHSCT. Prior therapy included both
anthracycline-containing regimens (in 21 patients) and thalido-
mide-containing regimens (in 14 patients). Two patients had not
received prior chemotherapy. All patients successfully achieved the
target of 2.5  106 CD34 cells/kg in either 1 (17 of 23 patients)
or 2 (6 of 23 patients) collections, with the ﬁrst apheresis product
containing a mean of 5.52  106 CD34 cells/kg. Analysis of
lymphocyte subsets by peripheral blood ﬂow cytometry demon-
strated no signiﬁcant differences before and after treatment with
bortezomib. All patients successfully engrafted with a median time
to neutrophil engraftment (ANC  500/mm3) of 11 days (range,
9–14 days). Platelet engraftment (time to platelet count  20,000/
mm3 sustained for 7 days without transfusion) occurred at a median
of 11 days (range, 9–30 days). Seventeen patients were evaluable
for response at 100 days posttransplantation. Compared with pre-
bortezomib paraprotein levels, 5 patients achieved a CR or near
CR, 11 maintained a PR, and 1 patient developed PD. We con-
clude that pretransplantation treatment with 2 cycles of bort-
ezomib given in sequence after anthracycline- or thalidomide-
containing chemotherapy does not adversely affect stem cell yield
or time to engraftment in patients with MM undergoing AHSCT.
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SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION TO TREAT DIF-
FUSE LARGE B-CELL LYMPHOMA WITH A HISTORY OF CENTRAL NER-
VOUS SYSTEM INVOLVEMENT, BONE MARROW INVOLVEMENT, OR
HISTOLOGICAL TRANSFORMATION
Hayes-Lattin, B., Mehta, P., Dunn, A., Subbiah, N., Leis, J.F.,
Simic, A., Allen, B., Balleisen, S., Curtin, P.T., Epner, E.,
Fleming, W.H., Jacoby, C., Mauro, M.J., Nichols, C.R., Schubach, S.,
Maziarz, R.T. Oregon Health Sciences University Cancer Institute,
Portland, OR.
Background: Patients with diffuse large B-cell lymphoma (DL-
BCL) who present with extranodal involvement or histological
transformation from low-grade disease have lower rates of survival
after conventional-dose therapy. The impact of these features on
outcomes after high-dose therapy with autologous transplantation
was investigated. Methods: We retrospectively reviewed the out-
comes of 64 consecutive patients receiving autologous transplan-
tation from 1995 to 2003 for the treatment of DLBCL. Variables
analyzed were age, gender, histological transformation, history of
bone marrow involvement, history of central nervous system
(CNS) involvement, time from diagnosis to transplantation, num-
ber of pretransplantation regimens, chemosensitivity before trans-
plantation, conditioning regimen, year of transplantation, and the
use of peripheral blood or bone marrow stem cells. Survivals were
estimated by the Kaplan-Meier method. The Cox proportional
hazards regression model was used to test the signiﬁcance of factors
on survival. Correlation between variables was tested with Spear-
man’s rank coefﬁcient. Results: The median age at transplantation
was 53.5 years. The median overall survival was 3.3 years, disease-
free survival was 1.2 years, and 100-day mortality was 7%. Among
a total of 29 patients, 12 had a history of CNS involvement, 10 had
a history of bone marrow involvement, and 12 had transformed
from low-grade lymphoma. A Cox regression analysis performed
to assess multivariate factors for survival suggested 2 regimens
before transplantation (log-rank test, P  .05) and the lack of
BEAM as the conditioning regimen (log-rank test, P  .02) as
signiﬁcant for overall survival. However, the use of BEAM was
highly associated with older age (r2  .42; P  .001) and more
prior chemotherapy regimens (r2 .24; P  .05). A history of
extranodal involvement, including prior CNS involvement (P 
.84) or bone marrow involvement (P  .52), was not associated
with lower survival by univariate analysis. No signiﬁcant associa-
tion was found between survival and a history of transformation
(P  .48). Conclusions: A history of CNS involvement, bone
marrow involvement, or histological transformation was not asso-
ciated with lower rates of survival among patients undergoing
autologous transplantation for DLBCL. Patients who present with
these clinical presentations remain candidates for autologous trans-
plantation.
Poster Session II
77BB&MT
